Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

This Veterans Day, columnist Samuel Kirton writes about the PACT Act, which expanded coverage for veterans exposed to toxic substances.

A Phase 2 trial testing experimental therapy CAL101 in people with IPF is recruiting participants. CAL101 has been granted ...

Columnist Samuel Kirton has nothing but praise for caregivers, who represent the best of what is right in the world.

Blocking caspase-9, an enzyme involved in cell death, may be a potential treatment target for pulmonary fibrosis, a ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

The Phase 3 REBUILD clinical trial, which tested Bellerophon Therapeutics‘ inhaled nitric oxide therapy INOpulse in people with pulmonary fibrosis at risk of developing pulmonary hypertension, failed ...

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

[vc_row][vc_column][vc_column_text]Pulmonary fibrosis (PF) is a respiratory disease that causes the lung tissue to become thick and stiff. Over time, it turns into scar tissue, which is known as ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...